Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Phase 4
40
about 1.4 years
6–17
1 site in IL
What this study is about
Researchers are testing if dupilumab can improve sleep, reduce itching (pruritus), and help with circadian rhythm problems in children with moderate to severe atopic dermatitis. The trial will involve giving children dupilumab for 12 weeks and then having them undergo overnight sleep studies before and after treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dupilumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
dupilumab
Primary: PROMIS (Patient Reported Outcome Measurement Information System) parent-proxy score, PROMIS patient score
Dermatology